Skip to main content

Advertisement

SpringerLink
Log in

Metabolic syndrome in children and adolescents

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Metabolic syndrome is a constellation of interrelated risk factors of metabolic origin that often accompany obesity and consist of atherogenic dyslipidemia, elevated blood pressure, impaired glucose tolerance, a prothrombotic state, and a proinflammatory state. Using a modification of the criteria by the National Cholesterol Education Program Adult Treatment Panel III, metabolic syndrome in children and adolescents can be clinically diagnosed when three or more of the following are present: body mass index ≥ 2 z score, systolic or diastolic blood pressure greater than 95th percentile, triglyceride level greater than 95th percentile, and/or high-density lipoprotein cholesterol less than 5th percentile and impaired glucose tolerance (fasting glucose > 110 mg/dL [6.1 mmol/L]). The prevalence of the metabolic syndrome in adolescents has been shown to be 4% overall, but it is 30% to 50% in overweight adolescents. In the United States, 18% to 22% of children and adolescents are overweight; the prevalence of a metabolic syndrome phenotype among US adolescents has also been increasing significantly over the past decade. All of the features of metabolic syndrome are risk factors for atherosclerosis, and metabolic syndrome has been shown to constitute risk for atherosclerotic cardiovascular disease in adults. In children and adolescents with metabolic syndrome, biomarkers of an increased risk of adverse cardiovascular outcomes are already present. Therefore, there is need for prevention and treatment of metabolic syndrome in this population. The mainstay of the treatment is dietary intervention and promotion of active lifestyle to achieve and maintain optimum weight, normal blood pressure, and normal lipid profile for the height and age. The pharmaceutical intervention is usually not required and its long-term outcome has not been studied. There is need for large studies for the management and long-term outcomes of metabolic syndrome in children and adolescents if the future tides of cardiovascular and other associated complications of metabolic syndrome are to be turned around.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1998, 37:1595–1607.

    Article  Google Scholar 

  2. ReFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173–194.

    Article  Google Scholar 

  3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report [no authors listed]. Circulation 2002, 106:3143–3421.

  4. Grundy SM, Cleeman JI, Daniels SR, et al: Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735–2752.

    Article  PubMed  Google Scholar 

  5. Grundy SM: Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006, 47:1093–1100.

    Article  PubMed  CAS  Google Scholar 

  6. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and the risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003, 107:391–397.

    Article  PubMed  Google Scholar 

  7. Ridker PM, Wilson PW, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004, 109:2818–2825.

    Article  PubMed  CAS  Google Scholar 

  8. Alberti KGMM, Zimmet P, Shaw J: The metabolic syndrome—a new worldwide definition. The IDF Epidemiology Task Force Consensus Group. Lancet 2005, 366:1059–1062.

    Article  PubMed  Google Scholar 

  9. Cook S, Weitzman M, Auinger P, et al: Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med 2003, 157:821–827. Important reference article for epidemiologic study on metabolic syndrome in children and adolescents.

    Article  PubMed  Google Scholar 

  10. Weiss R, Dziura J, Burgert TS, et al: Obesity and the metabolic syndrome in children adolescents. N Engl J Med 2004, 350:2362–2374. Important reference article and insight on the prevalence of metabolic syndrome in children and adolescents.

    Article  PubMed  CAS  Google Scholar 

  11. Ronnemaa T, Knip M, Lautala P, et al: Serum insulin and other cardiovascular risk indicators in children, adolescents and young adults. Ann Med 1991, 23:67–72.

    PubMed  CAS  Google Scholar 

  12. Duncan GE, Li SM, Zhou X-H: Prevalence and trends of a metabolic syndrome phenotype among U.S. adolescents, 1999–2000. Diabetes Care 2004, 27:2438–2443.

    Article  PubMed  Google Scholar 

  13. Dandona P, Aljada A, Chaudhuri A, et al: Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005, 111:1448–1454.

    Article  PubMed  Google Scholar 

  14. Mooradian AD, Haas MJ, Wong NC: Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes 2004, 53:513–520.

    Article  PubMed  CAS  Google Scholar 

  15. Tripathy D, Mohanty P, Dhindsa S, et al: Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003, 52:2882–2887.

    Article  PubMed  CAS  Google Scholar 

  16. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87–91.

    Article  PubMed  CAS  Google Scholar 

  17. Xu H, Barnes GT, Yang Q, et al: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821–1830.

    Article  PubMed  CAS  Google Scholar 

  18. La Cava A, Alviggi C, Matarese G: Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med 2004, 82:4–11.

    Article  PubMed  CAS  Google Scholar 

  19. Kubota N, Terauchi Y, Yamauchi T, et al: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002, 277:25863–25866.

    Article  PubMed  CAS  Google Scholar 

  20. Lakka HM, Laaksonen DE, Lakka TA, et al: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709–2716. Important reference on association of metabolic syndrome with increased risk of cardiovascular disease mortality in adults.

    Article  PubMed  Google Scholar 

  21. Malik S, Wong ND, Franklin SS, et al: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110:1245–1250.

    Article  PubMed  Google Scholar 

  22. Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). Diabetes 2003, 52:1210–1214.

    Article  PubMed  CAS  Google Scholar 

  23. Resnick HE, Jones K, Ruotolo G, et al: Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart study. Diabetes Care 2003, 26:861–867.

    Article  PubMed  Google Scholar 

  24. Klein BE, Klein R, Lee KE: Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care 2002, 25:1790–1794.

    Article  PubMed  Google Scholar 

  25. Koskinen P, Manttari M, Manninen V, et al: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992, 15:820–825.

    Article  PubMed  CAS  Google Scholar 

  26. Manson JAE, Colditz GA, Stampfer MJ, et al: A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991, 151:1141–1147.

    Article  PubMed  CAS  Google Scholar 

  27. McGill HC Jr, McMahan CA, Malcom GT, et al: Effects of serum lipoproteins and smoking on atherosclerosis in young men and women: the PDAY Research Group: Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol 1997, 17:95–106.

    PubMed  Google Scholar 

  28. Celermajer DS, Sorensen KE, Gooch VM, et al: Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111–1115.

    Article  PubMed  CAS  Google Scholar 

  29. Newman WP III, Freedman DS, Voors AW, et al: Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med 1986, 314:138–144.

    Article  PubMed  Google Scholar 

  30. Berenson GS, Srinivasan SR, Bao W, et al: Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998, 338:1650–1656.

    Article  PubMed  CAS  Google Scholar 

  31. Koenig W, Sund M, Frohlich M, et al: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middleaged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99:237–242.

    PubMed  CAS  Google Scholar 

  32. Ford ES: C-reactive protein concentration and cardiovascular disease risk factors in children: findings from the National Health and Nutrition Examination Survey 1999–2000. Circulation 2003, 108:1053–1058.

    Article  PubMed  CAS  Google Scholar 

  33. Zietz B, Herfarth H, Paul G, et al: Adiponectin represents an independent cardiovascular risk factor predicting serum HDL cholesterol levels in type 2 diabetes. FEBS Lett 2003, 545:103–104.

    Article  PubMed  CAS  Google Scholar 

  34. Tounian P, Aggoun Y, Dubern B, et al: Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001, 358:1400–1404.

    Article  PubMed  CAS  Google Scholar 

  35. Iannuzzi A, Licenziati MR, Acampora C, et al: Increased carotid intima-media thickness and stiffness in obese children. Diabetes Care 2004, 27:2506–2508.

    Article  PubMed  Google Scholar 

  36. Leeson CP, Whincup PH, Cook DG, et al: Cholesterol and arterial distensibility in the first decade of life: a population-based study. Circulation 2000, 101:1533–1538.

    PubMed  CAS  Google Scholar 

  37. Daniels SR, Arnett DK, Eckel RH, et al: Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation 2005, 111:1999–2012.

    Article  PubMed  Google Scholar 

  38. Dietz WH, Robinson TN: Overweight children and adolescents. N Engl J Med 2005, 352:2100–2109. Important reference article for the management of obesity in children and adolescents.

    Article  PubMed  CAS  Google Scholar 

  39. Barlow SE, Dietz WH: Obesity evaluation and treatment: expert committee recommendations. Pediatrics 1998, 102:e29.

    Article  PubMed  CAS  Google Scholar 

  40. Panel on Macronutrients, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes: Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). Washington, DC: National Academies Press; 2002.

    Google Scholar 

  41. Williams CL, Hayman LL, Daniels SR, Robinson TN, et al: Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2002, 106:143–160.

    Article  PubMed  Google Scholar 

  42. US Department of Agriculture: The Food Guide Pyramid for Young Children. Available at http:// www.cnpp.usda.gov/KidsPyra. Accessed June 16, 2006.

  43. Carnethon MR, Gidding SS, Nehgme R, et al: Cardiorespiratory fitness in young adulthood and the development of cardiovascular disease risk factors. JAMA 2003, 290:3092–3100.

    Article  PubMed  CAS  Google Scholar 

  44. Epstein LH, Paluch RA, Gordy CC, Dorn J: Decreasing sedentary behaviors in treating pediatric obesity. Arch Pediatr Adolesc Med 2000, 154:220–226.

    PubMed  CAS  Google Scholar 

  45. Summerbell CD, Ashton V, Campbell KJ, et al: Interventions for treating obesity in children. Cochrane Database Syst Rev 2003, 3:CD001872.

    PubMed  Google Scholar 

  46. Epstein LH, Valoski A, Wing RR, McCurley J: Ten-year outcomes of behavioral family-based treatment for childhood obesity. Health Psychol 1994, 13:373–383.

    Article  PubMed  CAS  Google Scholar 

  47. Epstein LH, Myers MD, Raynor HA, Saelens BE: Treatment of pediatric obesity. Pediatrics 1998, 101:554–570.

    PubMed  CAS  Google Scholar 

  48. Tonstad S, Thompson GR: Management of hyperlipidemia in the pediatric population. Curr Treat Options Cardiovasc Med 2004, 6:431–437.

    Article  PubMed  Google Scholar 

  49. Stein EA, Illingworth DR, Kwiterovich PO Jr, et al: Efficacy and safety of lovastatin in adolescents males with heterozygous familial hypercholesterolemia. A randomized controlled trial. JAMA 1999, 281:137–144.

    Article  PubMed  CAS  Google Scholar 

  50. McCridle BW, Ose L, Marais AD: Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2003, 143:74–80.

    Article  CAS  Google Scholar 

  51. Wiegman A, Hutten BA, de Grott E, et al: Statin therapy in hypercholesterolemic children. Long-term efficacy and safety [abstract]. Circulation 2003, 108(suppl):527.

    Google Scholar 

  52. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL: Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled clinical trial. JAMA 2003, 289:1805–1812.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Division of Cardiology, St. Louis Children’s Hospital, One Children’s Place, 5 South Suite 30, 63132, St. Louis, MO, USA

    Gautam K. Singh MD

Authors
  1. Gautam K. Singh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Singh, G.K. Metabolic syndrome in children and adolescents. Curr Treat Options Cardio Med 8, 403–413 (2006). https://doi.org/10.1007/s11936-006-0045-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-006-0045-3

Keywords

Search

Navigation